Cirrhosis and Liver Failure
MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis
Article first published online: 24 FEB 2013
© 2013 John Wiley & Sons A/S
Volume 33, Issue 5, pages 714–721, May 2013
How to Cite
Liver Int. 2013: 33: 714–721
- Issue published online: 7 APR 2013
- Article first published online: 24 FEB 2013
- Accepted manuscript online: 25 JAN 2013 12:43PM EST
- Manuscript Accepted: 19 JAN 2013
- Manuscript Received: 3 SEP 2012
- skeletal muscle;
Chronic diseases, including cirrhosis, are often accompanied by protein-energy malnutrition and muscle loss, which in turn negatively affect quality of life, morbidity and mortality. Unlike other chronic conditions, few data are available on the molecular mechanisms underlying muscle wasting in this clinical setting.
To assess mechanisms of muscle atrophy in patients with cirrhosis.
Nutritional [subjective global assessment (SGA) and anthropometry] and metabolic assessment was performed in 30 cirrhotic patients awaiting liver transplantation.
Rectus abdominis biopsies were obtained intraoperatively in 22 cirrhotic patients and in 10 well-nourished subjects undergoing elective surgery for non-neoplastic disease, as a control group. Total RNA was extracted and mRNA for atrogenes (MuRF-1, Atrogin-1/MAFbx), myostatin (MSTN), GSK3β and IGF-1 was assayed.
A total of 50% of cirrhotic patients were malnourished based on SGA, while 53% were muscle-depleted according to mid-arm muscle area (MAMA<5th percentile). MuRF-1 RNA expression was significantly increased in malnourished cirrhotic patients (SGA-B/C) vs. well-nourished patients (SGA-A) (P = 0.01). The phosphorylation of GSK3β was up-regulated in cirrhotic patients with hepatocellular carcinoma (HCC) vs. patients without tumour (P < 0.05).
Muscle loss is frequently found in end-stage liver disease patients. Molecular factors pertaining to signalling pathways known to be involved in the regulation of muscle mass are altered during cirrhosis and HCC.